CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
09-10-2019
CMA accuses 4 pharma companies of anti-competitive conduct
24-05-2019
30-11-2020
Sureeporn Teerasatean / Shutterstock.com
The UK Competition and Markets Authority (CMA) is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Essential Pharma, Priadel, competition, DHSC, Camcolit, Competition and Markets Authority, bipolar drug, CMA